<DOC>
	<DOC>NCT00140348</DOC>
	<brief_summary>The purpose of this study is to evaluate clinical and laboratory safety in patients receiving 4 different doses of GVAX® Prostate Cancer Vaccine in order to determine a maximum tolerated dose.</brief_summary>
	<brief_title>Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Diagnosis of adenocarcinoma of the prostate Metastatic prostate cancer deemed to be unresponsive or refractory to hormone therapy Detectable metastases ECOG performance status of 0 or 1 Transitional cell, small cell, neuroendocrine, or squamous cell prostate cancer Significant cancer related pain Prior gene therapy, chemotherapy, or immunotherapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Prostate</keyword>
	<keyword>Cancer</keyword>
	<keyword>Advanced Prostate Cancer</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Hormone-refractory</keyword>
	<keyword>GVAX</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Allogeneic cells</keyword>
</DOC>